Abstract:West Nile virus (WNV) is the leading cause of epidemic arboviral encephalitis in the United States. As there are currently no proven antiviral therapies or licensed human vaccines, understanding the neuropathogenesis of WNV is critical for rational therapeutic design. In WNV-infected mice, the depletion of microglia leads to enhanced viral replication, increased central nervous system (CNS) tissue injury, and increased mortality, suggesting that microglia play a critical role in protection against WNV neuroinvasive disease. To determine if augmenting microglial activation would provide a potential therapeutic strategy, we administered granulocyte-macrophage colony-stimulating factor (GM-CSF) to WNV-infected mice. Recombinant human GM-CSF (rHuGMCSF) (sargramostim [Leukine]) is an FDA-approved drug used to increase white blood cells following leukopenia-inducing chemotherapy or bone marrow transplantation. Daily treatment of both uninfected and WNV-infected mice with subcutaneous injections of GM-CSF resulted in microglial proliferation and activation as indicated by the enhanced expression of the microglia activation marker ionized calcium binding adaptor molecule 1 (Iba1) and several microglia-associated inflammatory cytokines, including CCL2 (C-C motif chemokine ligand 2), interleukin 6 (IL-6), and IL-10. In addition, more microglia adopted an activated morphology as demonstrated by increased sizes and more pronounced processes. GM-CSF-induced microglial activation in WNV-infected mice was associated with reduced viral titers and apoptotic activity (caspase 3) in the brains of WNV-infected mice and significantly increased survival. WNV-infected ex vivo brain slice cultures (BSCs) treated with GM-CSF also showed reduced viral titers and caspase 3 apoptotic cell death, indicating that GM-CSF specifically targets the CNS and that its actions are not dependent on peripheral immune activity. Our studies suggest that stimulation of microglial activation may be a viable therapeutic approach for the treatment of WNV neuroinvasive disease. IMPORTANCE Although rare, WNV encephalitis poses a devastating health concern, with few treatment options and frequent long-term neurological sequelae. Currently, there are no human vaccines or specific antivirals against WNV infections, so further research into potential new therapeutic agents is critical. This study presents a novel treatment option for WNV infections using GM-CSF and lays the foundation for further studies into the use of GM-CSF as a treatment for WNV encephalitis as well as a potential treatment for other viral infections.

West Nile virus—induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons

Axonal Transport Mediates West Nile Virus Entry Into The Central Nervous System And Induces Acute Flaccid Paralysis

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model

West Nile virus preferentially transports along motor neuron axons after sciatic nerve injection of hamsters

Immunization with Heterologous Flaviviruses Protective Against Fatal West Nile Encephalitis

Motor Unit Number Estimation As a Therapeutic Marker in Acute and Persistent West Nile Virus Infection in Hamsters

Neurological Approaches for Investigating West Nile Virus Disease and Its Treatment in Rodents

Persistent West Nile Virus Associated with a Neurological Sequela in Hamsters Identified by Motor Unit Number Estimation.

Neurological Suppression of Diaphragm Electromyographs in Hamsters Infected with West Nile Virus

Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival

Development and evaluation of neutralizing antibodies for cross-protection against West Nile virus and Japanese encephalitis virus

Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing.

Baboon model for West Nile virus infection and vaccine evaluation

Neurological approaches for investigating West Nile virus disease and its treatment in rodents.

Autonomic deficit not the cause of death in West Nile virus neurological disease

Phrenic nerve deficits and neurological immunopathology associated with acute West Nile virus infection in mice and hamsters

Autonomic Nervous Dysfunction In Hamsters Infected With West Nile Virus

Equine Immunoglobulin and Equine Neutralizing F(ab′)2 Protect Mice from West Nile Virus Infection

Memantine Treatment Reduces the Incidence of Flaccid Paralysis in a Zika Virus Mouse Model of Temporary Paralysis with Similarities to Guillain-Barré Syndrome

Clinical and Diagnostic Features of West Nile Virus Neuroinvasive Disease in New York City